191 related articles for article (PubMed ID: 22912756)
1. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P; Narjoz C; Golmard JL; Thomas-Schoemann A; Mir O; Taieb F; Durand JP; Coriat R; Dauphin A; Vidal M; Tod M; Loriot MA; Goldwasser F; Blanchet B
PLoS One; 2012; 7(8):e42875. PubMed ID: 22912756
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
Bins S; Lenting A; El Bouazzaoui S; van Doorn L; Oomen-de Hoop E; Eskens FA; van Schaik RH; Mathijssen RH
Pharmacogenomics; 2016 Sep; 17(14):1483-90. PubMed ID: 27533851
[TBL] [Abstract][Full Text] [Related]
3. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Tandia M; Mhiri A; Paule B; Saffroy R; Cailliez V; Noé G; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2017 Apr; 79(4):759-766. PubMed ID: 28289864
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
[TBL] [Abstract][Full Text] [Related]
5. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
Boudou-Rouquette P; Ropert S; Mir O; Coriat R; Billemont B; Tod M; Cabanes L; Franck N; Blanchet B; Goldwasser F
Oncologist; 2012; 17(9):1204-12. PubMed ID: 22752067
[TBL] [Abstract][Full Text] [Related]
6. Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Toffalorio F; Spitaleri G; Catania C; Dal Zotto L; Noberasco C; Delmonte A; Santarpia M; Vecchio F; Brunelli V; Rampinelli C; Barberis M; Fumagalli C; Zucchetti M; Zangarini M; Diena T; Danesi R; de Braud F; De Pas T
Oncologist; 2014 Apr; 19(4):344-5. PubMed ID: 24674875
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
Tsuchiya N; Narita S; Inoue T; Hasunuma N; Numakura K; Horikawa Y; Satoh S; Notoya T; Fujishima N; Hatakeyama S; Ohyama C; Habuchi T
Anticancer Drugs; 2013 Mar; 24(3):310-4. PubMed ID: 23237922
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
9. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
[TBL] [Abstract][Full Text] [Related]
12. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
[TBL] [Abstract][Full Text] [Related]
14. In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
Mai H; Huang J; Zhang Y; Qu N; Qu H; Mei GH; Liu J; Xu X; Chen L
Oncotarget; 2017 Jun; 8(26):43458-43469. PubMed ID: 28404979
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Puzanov I; Sosman J; Santoro A; Saif MW; Goff L; Dy GK; Zucali P; Means-Powell JA; Ma WW; Simonelli M; Martell R; Chai F; Lamar M; Savage RE; Schwartz B; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):159-68. PubMed ID: 25294187
[TBL] [Abstract][Full Text] [Related]
16. Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
Shin SY; Lee YJ
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):837-46. PubMed ID: 24075093
[TBL] [Abstract][Full Text] [Related]
17. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Li Y; Li S; Zhu Y; Liang X; Meng H; Chen J; Zhang D; Guo H; Shi B
J Clin Hypertens (Greenwich); 2014 Mar; 16(3):177-85. PubMed ID: 24621095
[TBL] [Abstract][Full Text] [Related]
20. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
